Trials / Terminated
TerminatedNCT01479010
Pilot Study of the Safety and Efficacy of Anakinra (Recombinant Human Interleukin-1 Receptor Antagonist) in Pulmonary Hypertension
- Status
- Terminated
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 2 (actual)
- Sponsor
- Virginia Commonwealth University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is an open-label non-randomized, pilot study to evaluate the effect of Interleukin-1 blockade on exercise capacity in patients with pulmonary hypertension. Subjects will undergo cardiopulmonary exercise testing at baseline, and after 4 weeks treatment with Anakinra (recombinant human Interleukin-1 receptor antagonist.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Anakinra 100 mg subcutaneously daily | Anakinra 100 mg subcutaneously daily |
Timeline
- Start date
- 2011-11-01
- Primary completion
- 2013-11-01
- Completion
- 2013-11-01
- First posted
- 2011-11-24
- Last updated
- 2017-11-13
- Results posted
- 2015-06-08
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01479010. Inclusion in this directory is not an endorsement.